‘Easy to handle’ Cereblon – a new tool for drug discovery and molecular glue screening
Targeted protein degradation (TPD) is an emerging therapeutic strategy that hijacks the cellular recycling machinery to degrade and...
top of page
Nov 19
Two PROXIDRUGS project leaders recognized as highly cited researchers
With Ivan Đikić and Gerhard Hummer two PROXIDRUGS Project Leaders are recognized as Highly Cited Researchers in their fields on...
Nov 15
International collaboration discovers role of ubiquitination and ER phagy in combatting defective splicing
In a study published in today’s issue of Science, a team around PROXIDRUGS speaker Ivan Đikić reveals how cells deploy ubiquitination and...
Oct 21
Ivan Đikić receives LOEWE-Spitzenprofessur
PROXIDRUGS speaker Ivan Đikić has been awarded a prestigious LOEWE-Spitzenprofessur at Goethe University Frankfurt. The Hessian LOEWE...
Aug 22
PROXIDRUGS Cluster4Future funded for a further three years
The PROXIDRUGS consortium was successfully evaluated by an independent jury and will be funded by the Federal Ministry of Education and...
Aug 20
Hausch team synthesizes ultrapotent binder for challenging protein targets
In their latest publication in Chemistry, PROXIDRUGS project leader Felix Hausch and colleagues present the design of ultrapotent FKBP...
Jul 14
MC4DD: TU Darmstadt successfully obtains new EU-funds for doctoral network dedicated to drug discovery
PRODXIDRUGS project leader Felix Hausch at TU Darmstadt is coordinating a newly established doctoral network, which is funded by the...
Jun 6
Ivan Đikić among Top Molecular Biology Scientists - 2024 Research.com ranking
PROXIDRUGS speaker Ivan Đikić ranked #7 in Germany and #141 in the world on Research.com’s 2024 list of ‚Best Molecular Biology...
May 30
Funding decision for Collaborative Research Centre “UbiCancer” (CRC/TRR 387)
Today, the German Research Foundation (DFG) announced that the transregional CRC on functionalisation of the ubiquitin system against...
May 24
Thalidomide derivatives degrade BCL-2 by reprogramming the binding surface of CRBN
PROXIDRUGS member Xinlai Cheng and his team published their work on how thalidomide derivatives degrade BCL-2, providing important clues...
bottom of page